Gastric cancer (GC) is one of the most common malignancies worldwide. Most patients are
diagnosed at advanced stages due to the subtle symptoms of earlier disease and the low …

Tumor mutational burden (TMB), defined as the number of somatic mutations per megabase
of interrogated genomic sequence, varies across malignancies. Panel sequencing–based …

Platinum-based chemotherapy is the standard first-line treatment for advanced esophageal
squamous cell carcinoma (ESCC). In this phase 3 study (ClinicalTrial. gov: NCT03829969) …

Gastric cancer (GC) is one of the most malignant human cancers with increasing incidence
worldwide, ranking among the top five malignant tumors worldwide in terms of incidence …

There exist differences in the epidemiological characteristics, clinicopathological features,
tumor biological characteristics, treatment patterns, and drug selections between gastric …

Advanced intrahepatic cholangiocarcinoma (ICC) has a dismal prognosis. Here, we report
the efficacy and safety of combining toripalimab, lenvatinib, and gemcitabine plus oxaliplatin …

Abstract Background Dysregulation of circular RNAs (circRNAs) plays an important role in
the development of gastric cancer; thus, revealing the biological and molecular mechanisms …

Gastric cancer (GC) represents an important contributor to the global burden of cancer,
being one of the most common and deadly malignancies worldwide. According to TCGA and …

PURPOSE The CHOICE-01 study investigated the efficacy and safety of toripalimab in
combination with chemotherapy as a first-line treatment for advanced non–small-cell lung …

Background Pembrolizumab, an anti-PD-1 antibody, results in tumour response in around
15% of patients with advanced gastric cancer who have a PD-L1 combined positive score of …